Q.D. Research, Inc., Granite Bay, CA
Sacha Satram-Hoang , Carolina M. Reyes , Alisha Stein , Khang Q. Hoang , Faiyaz Momin , Patricia Cortazar
Background: Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) is the most common biologic subtype of breast cancer (BC). We examined treatment patterns and outcomes associated with adjuvant or neoadjuvant therapy among elderly patients (pts) in the US. Methods: The analysis included 18,470 first primary HR+HER2- BC pts from the linked SEER-Medicare database. Pts were diagnosed with Stage I-III disease between 1/1/2007-12/31/2011, ≥66 years, continuously enrolled in Medicare Parts A/B in the year prior to diagnosis, enrolled in Part D in the year after diagnosis, and underwent BC surgery ≤6 months after diagnosis. Time-varying Cox proportional hazards regression assessed overall survival adjusting for pt characteristics. Date of last follow-up was 12/31/2013. Results: There were 13,670 (74%) pts treated with hormonal therapy +/- chemotherapy and 4,800 (26%) untreated. Compared to treated pts, untreated pts were older, had earlier stage, lower grade, smaller tumors, poorer performance, higher comorbidity, and less genomic testing for risk of recurrence (p<0.0001). In a multivariate analysis, increasing age, stage, tumor size, tumor grade, comorbidity score and poor performance were significantly associated with higher mortality risks, while use of genomic testing was associated with a lower risk of death. The Cox model showed a 48% higher risk of death in untreated compared to treated pts (HR=1.48; 95% CI=1.35-1.61). Even in a subset of 8,967 pts with stage I disease, tumor size <2.0cm and grade 1/2; untreated pts had a 22% higher risk of death compared to treated pts (HR=1.22; 95% CI=1.05-1.41). Conclusions: Patients who are older with favorable disease characteristics (earlier stage, smaller tumor, lower grade) are less likely to be treated and have a higher risk of death compared to pts who received adjuvant or neoadjuvant therapy. The unmet need among elderly BC pts remains, suggesting that age should not deter guideline-based therapy.
Treated N=13670 | Untreated N=4800 | |
---|---|---|
Mean Age* (95% CI) | 74.7 (74.6-74.8) | 78.0 (77.8-78.2) |
Stage*, (%) | ||
1 | 56 | 70 |
2 | 34 | 25 |
3 | 9 | 5 |
Grade*, (%) | ||
1 | 29 | 35 |
2 | 49 | 47 |
3/4 | 18 | 14 |
Tumor Size <2.0cm*, (%) | 63 | 72 |
*p-value <0.001
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Irina Sorokina
2023 ASCO Annual Meeting
First Author: Natalija Dedic Plavetic
2022 ASCO Annual Meeting
First Author: Jamal Zidan
2020 ASCO Virtual Scientific Program
First Author: Cynthia X. Ma